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Abstract. Vaccine plays a very important role in human and domestic animal life for 
combating infectious diseases.  Existing and traditional methods of manufacturing vaccines in bulk to 
the required level of purity and quality are stretched to capacity and will soon become limiting in 
vaccine manufacturing. Moreover, traditional method of vaccine production is very expensive and is 
currently unaffordable by majority of the consumers. Plant-made vaccines (PMVs), on the other hand, 
offers unique opportunities to reduce cost significantly due to minimal investment requirement, ease 
and economy of scale-up, lack of risk of contamination with human pathogens, etc. There is a 
substantial and increasing worldwide demand for vaccines. Specialized plant-based gene-expression 
technologies are ready to provide an alternative manufacturing platform that can help meet the demand 
and thus overcome the perceived ―bottleneck‖ in vaccine production; and taken together, these 
situations make a strong case for commercial development of PMVs. A particularly attractive feature 
of the PMV is its potential to provide opportunities for both the agricultural sector and the 
biotechnology business sector simultaneously. Several Plant Biotechnology companies are already 
actively working in this area and worldwide many PMVs are at different stages of discovery through 
human clinical trials. PMV is currently an exciting and expanding area of plant biotechnology with 
great potentials to offer affordable vaccines to underprivileged population of the world. A large variety 
of host plants and expression systems have already been developed to deliver PMVs. However, there 
are concerns of low transgene expression, transgene escape, dose optimization and need for minor 
processing before oral delivery. The current status of achievements, challenges and opportunities will 
be covered in this review. 
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INTRODUCTION  
 
Of the approximately 15 million deaths worldwide every year from infectious 
diseases, over 9.5 million people die in developing countries (Morens et al., 2004; Who, 
2008). Therefore, there is an urgent need to develop cost-effective treatment against serious 
infectious diseases and much more efforts are needed to fulfil the health needs for these 
countries. To combat infectious diseases, vaccination is considered to be the most cost-
effective and efficient means for health intervention. However, the high cost of vaccination 
makes it unaffordable for most people living in developing countries, as the daily average 
income for nearly one billion people is less than one US$. Moreover, a 14-fold increase in the 
cost of vaccines over the past decade (Xu et al., 2007) makes it necessary to investigate 
alternative strategies for their production and delivery. Furthermore, the development of 
subunit vaccines (that use one or two proteins instead of whole avirulent or killed pathogen 
strains), with the use of recombinant expression systems is becoming more popular due to 
safety concerns. The complex production and delivery methods of current vaccines accounts 
for its high cost which includes the significant costs of fermentation and purification systems 
and additional expenses associated with adjuvant, cold storage, transportation and sterile 
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delivery (Daniell et al., 2009).Considering these factors, it is necessary to explore alternate 
production methods that should facilitate cost reduction at different levels. Plants present an 
alternative and attractive source for this purpose, as they can be grown at the site where 
production is needed and yield can be scaled up according to the demand. 
In the past 20 years, there has been extensive research on plant-based vaccines. The 
expectation of ‗cheap, edible vaccines‘ of the early years (Fooks, 2000; Rybicki, 2009a; 
2009b) has not been realized yet. The idea of using edible plants or fruits to deliver vaccines 
is still very attractive-largely because it means that vaccines could be ‗farmed‘ where they are 
needed, avoiding transport and cold chains, and oral delivery is easier and safer than injection. 
However, there are many practical problems with the concept for it to be implemented as 
envisioned. For example, quality control issues, uniform doses, and the physical 
administration of such vaccines needs to be regulated, as otherwise too much or too little 
could be given, and too frequently. Thus, the product itself will have to be processed to some 
extent, formulated in a reproducible way, and given under supervision so as to ensure 
reproducible effects (Rybicki, 2010). 
The major advantage of plant expression systems over other vaccine production 
systems is reduced manufacturing cost. Fermenters and bioreactors can be replaced with 
contained plant growth rooms or greenhouses or plants can be grown in the field with 
appropriate biological containment of foreign genes, such as maternal inheritance or male 
sterility, or expression in vegetative tissues with harvest before appearance of any 
reproductive structure (Daniell et al., 2009). This should lead to reduced upstream facility 
costs. In the case of oral plant-produced vaccines, downstream processing costs are also 
reduced. Instead of protein purification targeting up to 99% purity, plant tissues can be 
inexpensively processed for oral delivery. The relevant technology has already been 
developed in the food and feed industries and can be adapted for plant-produced vaccine 
proteins (Rybicki, 2010). 
In the last five years, a large number of review articles were published on plant-made 
pharmaceuticals in general and plant-made vaccines in particular (CoKu, 2007; Lossl and 
Waheed 2011; Pogue et al., 2010; Rybicki, 2009a; 2009b; 2010; Tacket 2009; Tiwari et al., 
2009). To educate our future generations this important topic for public awareness and also to 
make this topic interesting to High School Science teachers and biotechnology students, in 
this review I attempted to disseminate the potential for plant-made vaccine information in a 
more interesting way by emphasizing it from challenges and opportunities point of view. 
Currently there are three target systems to produce antigen proteins in plants. These 
are: Stable expression in nuclear genome, Stable expression in plastid genome, and transient 
expression systems for large-scale production. Each of these systems has challenges and also 
offers opportunities. In this review, current status of plant-made vaccine production of each 
target systems will be briefly described, the advantages and disadvantages of different plant 
expression systems, and their current challenges and opportunities will be evaluated. 
 
Stably integrated nuclear transgenes 
In the early stages of plant transformation technology development, stable integration 
of transgenes in nuclear genomes was the target and tobacco (Nicotianatabacum) was used as 
model plant due to its easy tissue culture and regeneration process. Therefore, the nuclear 
genome of tobacco was the first choice for stably transformed plants to express recombinant 
vaccine antigens using Agrobacterium-mediated delivery of DNA due to ease and already 
established nuclear transgene methodology. The stable nuclear transgene approach was the 
dominant strategy for several years due to the ability to scale up production of large amounts 
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of vaccine antigens from transgenic seed stocks and the expression in fruits or other edible 
plant organs. The expression in edible plant organs is an attractive approach for oral delivery 
with minimum processing of the transgenic material. However, the expression level of stably 
integrated nuclear transgenes is generally low (yield is <1% total soluble protein, TSP). The 
yield can also vary from plant to plant and generation to generation, maybe due to gene 
silencing or position effect (Voinet et al., 2003). 
Many different vaccine antigens have been produced in various plant species such as 
tobacco (Santi et al., 2006; Shoji et al., 2009); potato (Thanavala et al., 2005); tomato (Zhang 
et al., 2006; Alvarez et al., 2006; Jiang et al., 2007); rice (Nochi et al., 2007); carrot (Rosales-
Mandoza et al., 2008) and soybean (Moravec et al., 2007). Oral delivery of several plant-
derived antigens has elicited antigen-specific antibodies in mice and, in a few clinical trials, in 
humans (Arakawa et al., 1998; Tacket et al., 1998). Vaccine antigens derived from enteric 
pathogens, such as Norwalk virus capsid protein (NVCP), rotavirus capsid protein and the 
bacterial ganglioside-binding protein cholera toxin B subunit (CTB) and Escherichia coli 
heat-labile toxin B subunit (LTB), have been extensively evaluated in nuclear transgenic 
plants. For example, mice orally immunized with carrot-derived LTB (Rosales-Mandoza et 
al., 2008) or rice-derived CTB (Nochi et al., 2007) induce protection against cholera toxin 
(CT) challenge. Several other antigens from non-enteric pathogens such as F protein from 
respiratory syncytial virus (Sandhu et al., 2000) and surface antigen from hepatitis B (Richter 
et al., 2000; Thanavala et al., 2005) also stimulate antigen-specific antibodies after oral 
delivery. However, adjuvants might be required for such stimulation. For example, in the case 
of hepatitis B surface antigen (HBsAg) fed to mice in transgenic potato tubers (Kong et al., 
2001), it was necessary to useCT, a potent mucosal adjuvant, to stimulate significant levels of 
anti-HBsAg antibodies, although the same HBsAgpotatoes fed to humans without adjuvant 
provoked serumanti-HBsAg in most of the volunteers. 
The use of fresh, unprocessed plant materials as vaccines has limitations due to its 
shelf life and uniform dosage issue. Thus, for validated potency and stability some form of 
processing, such as freeze-drying must be applied to produce reproducible product batch. 
Both freeze- or air-dried and fresh transgenic tomato fruits showed similar immunogenic 
response for NVCP when fed orally (Zhang et al., 2006), but that was not the case for freeze-
dried potato as it produced poor results compared with fresh potato (Zhang et al., 2006), may 
be due to oxidation of phenolic compounds in dried potato. Thus, when tissues rich in 
phenolics and the enzyme polyphenol oxidase are used control of oxidation will be an 
important issue.The use of seed tissues is more promising due to its extended shelf life and 
stability for both human and animal vaccine candidates. For the development of veterinary 
products, seed-based vaccines are particularly attractive because of convenience in storageand 
delivery and have demonstrated promising results in farmed animal studies (Lamphear et al., 
2002). 
 
Chloroplast ⁄ plastid expression 
Although most early work has been focused on the use of nuclear transformation for 
antigen expression, it was soon realized the importance of plastid transformation especially 
chloroplast transformation for antigen expression to overcome low expression level. A recent 
review claims that the yield from the chloroplast transformation is so high that even it will be 
possible to combating bioterrorism (Streatfield, 2006). Protocols for chloroplast 
transformation, antigen expression and oral administration have recently been reviewed by 
Singh et al. (2009); most of the pioneering work was reported by Henry Daniell‘s group 
(Daniell, 2006; Dhingra and Daniell, 2006). 
 14 
Although in majority of the cases the protein expressed in chloroplast cannot undergo 
glycosylation which is a challenge of production of such proteins in large scale in a cost-
effective way. However, some exception was reported such as, the severe acute respiratory 
syndrome coronavirus (SARS-CoV) spike protein – a membrane associated glycoprotein – 
apparently accumulates well in transformed chloroplasts (Li et al., 2006). Another example is 
the high-level production LacAlectin fragment of the pathogen Entamoeba histolytica, in 
tobacco chloroplasts and the demonstration of very effective immunogenicity after 
subcutaneous immunization of mice produced high IgGtitres (Chebolu and Daniell, 2007). 
The authors reported an average yield of 24 mg of LecA per plant and according to them it 
should translate to 29 million doses of vaccine antigen per acre of transgenic plants. This is an 
important pathogen as it causes approximately 100,000 deaths annually. 
Other promising achievements include the highest expression level of HPV-16 L1 
protein in transplastomic tobacco (approximately 3 g⁄ kg). This protein not only assembled 
correctly but also elicited neutralizing antibodies (Fernandez-SanMillan et al., 2008). 
However, in another report suggest that the same protein expressed well in chloroplasts only 
when fused to a chloroplast protein fragment (Lenzi et al., 2008). The HIV-1 Pr55Gag protein 
has also been successfully produced at relatively high levels in transplastomic tobacco (to 
approximately 360 mg⁄ kg) and assembled into virus like particles (VLPs) similar to those 
produced in animal cells, which makes this the first vaccine-relevant HIV antigen to be 
produced in reasonable quantities in plants (Scotti et al., 2009). It is also possible that the 
glycosylation barrier may be overcome soon as well: novel pathways have been identified, 
which could allow in chloroplasts the kinds of protein maturation that occur in the ER and 
Golgi compartments (Faye and Daniell, 2006; Gomord et al., 2009). 
 
Transient expression systems 
In recent years, transient expression systems for large-scale production of plant-made 
vaccines has been an increasing trend due to sheer convenience and speed, although much of 
the early work was carried out with stably transformed plants or cells. Both virus vector-based 
and Agrobacterium infiltration-based systems offer the chance of getting large amounts of 
protein in days after the initial molecular cloning event, rather than the months necessary for 
transgenic expression (Fischer et al., 1999). 
 
Virus-based vectors 
As a transient expression system, initially viral vectors, mostly tobacco mosaic virus 
(TMV)-based, have been used to express foreign proteins or of chimeric coat proteins in 
plants (Gleba et al., 2007; Steinmetz et al., 2009). Large ScaleBiology Corp. (LSBC) had the 
recombinant TMV technology (Geneware) as one of their main products, and it was 
successfully used to express their flagship patient-specific non-Hodgkin lymphoma tumour-
derived single-chain Fv epitope vaccines for FDA-approved clinical trial (McCormick et al., 
2006, 2008). A significant proof of principle in an animal model was the successful use of 
rTMV expressing surface-located epitopes derived from cottontail rabbit papillomavirus 
(CRPV) and rabbit oral papillomavirus (ROPV) L2 minor capsid proteins as a protective 
injectable vaccine (Palmer et al., 2006). 
Other plant viruses have successfully been used for expression of whole antigens 
include the potexviruses potato virus X (PVX), bamboo mosaic virus (BaMV) and papaya 
mosaic virus (PapMV), cowpea mosaic comovirus (CPMV) (Canizares et al., 2005), bean 
yellow dwarf mastrevirus (BeYDV), the related alfalfa mosaic (AlMV) and cucumber mosaic 
viruses (CMV), and tomato bushy stunt tombusvirus, among others. Important proofs of 
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concept using these vehicles include the use of PVX-mediated expression of a human 
papilloma virus type 16 E7 oncoproteinin N. benthamiana, and the use of crude foliar extracts 
as a vaccine to protect mice against E7-producing tumour cell challenge (Franconi et al., 
2006); the use of chimeric BaMV virions displaying a partial sequence of FMDV VP1to 
induce both humoral and cell-mediated immune responses, and full protection against FMDV 
in pigs (Yang et al., 2007). 
When viral vectors are used, in many instances transgene loss is a common 
phenomenon. To overcome this challenge, plant viruses were redesigned, cloned between 
right and left border of T-DNA and Agrobacterium tumefaciens were used for systemic 
delivery of viral genomes. 
 
Agroinfiltration vectors 
Agroinfiltration, via syringe or vacuum is an Agrobacterium tumefaciens - mediated 
transient gene expression system in plant leaves with a suspension of the bacterium is a 
powerful method that can mobilize T-DNA containing gene of interest into the nuclei of a 
large proportion of the cells (Fischer et al., 1999). This is a great technique for determining 
whether or not any given gene can be expressed in plants. Since a wide variety of vectors 
available for intracellular targeting of expressed proteins, it can also be determined in which 
cell compartments the protein accumulates best. Moreover, optimization of expression of 
transgenes became simple when many constructs could be tested in parallel by syringe 
infiltration, using different versions of the same basic gene, different promoters and different 
leader or organelle targeting sequences (Rybicki, 2010). 
When transiently expressed HBsAg and an GFP::HBsAg fusion formed virus-like 
particles (VLPs) similar to yeast-derived vaccine HBsAg was one of the first proof that the 
Agrobacterium tumefaciens - mediated transient gene expression system could be used for 
high-throughput conformational screening of vaccine proteins for vaccine-related applications 
of the technology (Huang and Mason, 2004). An example from Rybicki‘s laboratory was the 
high-level (0.8 g⁄kg) expression of HPV-16 L1 protein in N. benthamiana, with the 
demonstration that protein accumulated better when exported to chloroplasts than in the 
cytoplasm, assembled into VLPs, and elicited neutralizing antibodies in mice after injection 
with or without adjuvant (Maclean et al., 2007). Although successful in expression of whole 
Pr55Gag (HIV Gag protein) only at very low levels is possible, but aGag-derived p17 ⁄ p24 
fusion protein could be expressed to 5 mg⁄kg if localized to chloroplasts and was a successful 
booster vaccine from both T-cell and humoral responses in mice primed by a gag DNA 
vaccine (Meyers et al., 2008). Another great example of the potential of plant agroinfiltration 
to produce an influenza vaccine is reported (D‘Aoust et al., 2008). They expressed 
haemagglutinin (HA) from H5N1 viruses in N. benthamianaby agroinfiltration and showed 
that the HAs yielded up to 50 mg⁄ kg, assembled correctly into trimers, and moreover budded 
at the plasma membrane at apoplastic indentations into VLPs largely devoid of host proteins. 
Furthermore, the purified H5-derivedVLPs were highly immunogenic: two doses of 0.5 µg 
ofH5-VLPs conferred complete protection against a lethal challenge with a heterologous 
virus. 
 
Agroinfiltrated viral vectors 
‗Magnifection‘ is the centerpiece of Agrobacterium tumefaciens - mediated transient 
gene expression system production technology of the new Icon Genetics (Halle, Germany). 
This technology is developed by combining agroinfiltration with delivery of cDNA encoding 
a ‗deconstructed‘ TMV-based vector which is one of the most significant developments in 
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this field (Gleba et al., 2005).The system was soon used to produce recombinant Yersinia 
pestis antigens F1, V and fusion protein F1-V. The purified antigens injected into guinea pigs 
were protective against an aerosol challenge of virulent Y. pestis (Santi et al., 2006). Although 
HBsAg was produced in a plant system earlier, the first acceptable production level of this 
antigen in a plant system was also achieved using MagnICONviral vectors (approximately 
300 mg⁄kg leaf fresh weight): the product was full length, had disulphide-linked dimers and 
assembled intoVLPs (Huang et al., 2008). Icon Genetics have recently reported the 
production of lifelong supplies of single - patient personalised non-Hodgkin lymphoma 
vaccines from as little as 5 kg of N. Benthamiana using MagnICON vectors to (Rybicki, 
2009b). Another success story was that human Norwalk noroviruscapsid vaccines could be 
easily and quickly produced with Icon technology (Dylewski, 2009; Rybicki, 2009b). ‗Launch 
vector‘, a novel version of an agroinfiltration-delivered TMV-based vector (Musiychuk et al., 
2007) has also been used to produce HPV E7 protein and H5N1 influenza virus 
haemagglutininand neuraminidase domains fused to athermostablelichenase (LickM): the 
fusions are apparently able to activate both innate and adaptive antigen-specific immune 
responses. The E7vaccine was protective against tumours in a mouse model (Massa et al., 
2007) and the H5-derivedvaccine was found to be protective against viral challenge in ferrets 
(Mett et al., 2008). The same technology was also used to produce Fraction 1(F1) and V 
antigens of Y. pestis, and demonstrated protection of cynomolgus macaques against 
aerosolized bacteria (Chichester et al., 2009b). 
Both the MagnICONand launch vectors are suitable for amplified expression in 
N.benthamianaonly which is a limited host range issue. This has been addressed both by Icon 
Genetics and Fraunhofer, USA, by using different plant viruses such as, improved TMV, 
turnip vein-clearing potyvirus and PVX vectors (Rybicki, 2009b), and Fraunhofer USA has 
investigated launch vectors comprising cucumber mosaic and alfalfa mosaic virus-derived 
constructs in Pisum sativum varieties (Green et al., 2009). 
Plant single-stranded DNA geminiviruses and nanoviruses, as well as CPMV are other 
new vector systems for amplified protein expression in plants. An improved 
geminivirussystems with or without the silencing suppressor protein P19 delivered via 
agroinfiltration was used to produce hepatitis B core antigen (HBc) and Norwalk virus capsid 
protein (NVCP) at high levels (Huang et al., 2009). Rybicki‘s group has also used a BeYDV-
based agroinfiltration-delivered single plasmid replicon system to significantly boost 
expression of HPV-16 L1 and HIV p24 and other vaccine proteins in N. benthamiana, 
compared to non replicating controls (Regnard et al., 2010). A novel gemini- and nanovirus 
based technology has been shown to be very effective in the inducible expression of proteins 
is the ‗In-Plant Activation technology‘ (INPACT) of Farmacule Bio-Industries (Vic., 
Australia): this is an inducible system that allows amplified replicon-based transgenic 
expression of even highly toxic molecules (Farmacule, 2009; Rybicki, 2009b) – but should 
prove equally useful in a transient expression setting. 
The CPMV-based technology derives from an extremelypotent translational enhancer 
– a modified 5‘-untranslatedregion (UTR) and the 3‘-UTR from CPMV RNA-2 (CPMVHT) – 
which allows agroinfiltration-mediated high-level simultaneous expression of multiple 
polypeptides from a single plasmid within a few days (Sainsbury et al., 2009). 
 
Optimization of expression 
The major bottleneck in plant-made vaccine protein production using stable nuclear 
gene expression system is the low level of expression considering the level that is acceptable 
for economic production (e.g. >50 mg⁄kg for antibodies). Even after more than 20 years of 
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research, in many cases yields have been so low that the establishment of proofs of efficacy 
has been very difficult. This is more relevant for oral vaccination schemes, as experiments 
have shown that for the same level of immune response to the same protein, even with the use 
of potent adjuvants, when taken orally it requires at least 10 fold more protein compared to 
parenteral intake. For example, in case of HBsAg when parenteral vaccination requires only 
40 µg dose for full immune response approximately 1 mg potato-produced HBsAgfrom oral 
boosting with three 100-g doses of potato containing HBsAg (Thanavala et al., 2005) in 
human clinical trial was only partially effective. Although much higher levels of HBsAg 
expression in plant have since been achieved (Huang et al., 2008), the dream of an oral HBV 
vaccine is still not a reality. Similar comparison of oral vs. parenteral dosing is applicable for 
HPV vaccine, where 10 µg were required to orally immunize mice for the same response 
elicited by injection of 1 µg (Gerber et al., 2001). 
To improve the expression of a plant-made vaccine protein, optimization 
experimentation is critical. It may be targeting the transgene to different organelles or use 
different expression system or changing the host plant. For example, optimization of 
expression of the cancer-associated human pathogen HPV-16 major capsid protein L1, by 
simply changing host from N. tabacum cv. ‗Xanthi‘ to SR1 allowed a 100-fold increase in 
expression of the native viral gene (Rybicki, 2010), chloroplast accumulation increased 
protein expression by a factor of 20-fold the previous best transgenicHPV-16 L1 yield. Scotti 
et al. (2009) have recently reported that it is possible to produce whole Pr55Gag protein, at 
levels up to 800 mg⁄kg, in transplastomictobacco. The fact that the protein assembled into 
VLPs like those produced in animal cell systems, and which are increasingly seen as potential 
HIV vaccines (Speth et al., 2008; Chege et al., 2009), means that a viable plant-derived T-cell 
stimulating HIV vaccine may finally be possible – and could even be orally administered, 
given the kinds of yield that were demonstrated. 
While it may be possible to some extent to predict ways of increasing recombinant 
protein expression in plants, the process is completely empirical. The automatic assumption 
that ‗plant codon usage‘ will be optimal is not valid. There is no one universally suitable host 
or production system, although the use of agroinfiltration and deconstructed plant viral 
vectors seems to be on the way to becoming an industry standard. Recently Kentucky 
Bioprocessing Group demonstrated the production of approximately 500 g of H1N1 protein 
using Megnifection technology in tobacco (Hyatt, 2011). It is advisable to explore all 
intracellular organelle and export targeting options, but also plastid transformation, as plastid 
targeting of proteins after cytoplasmic synthesis may not predict what happens with mRNA 
expression and translation in these organelles. It is also advisable to consider myristylation 
factor that may play a significant role when considering the expression of a membrane-
associating protein. 
 
Challenges, opportunities of plant-made vaccines 
 
1. Low expression levels of transgenes 
Challenges: The expression level of stably integrated nuclear transgenes is generally 
low (yield is <1% total soluble protein, TSP). However, to be acceptable for economic 
production >50 mg⁄ kg for antibodies are required. 
Opportunities: Since >10,000 copies of chloroplast genomes are present in each cell, 
very high level of expression of vaccine antigens can be achieved by chloroplast 
transformation. For example, the highest expression level of HPV-16 L1 protein 
(approximately 3 g⁄kg) was reported in transplastomic tobacco. Moreover, this protein not 
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only assembled correctly but also elicited neutralizing antibodies (Fernandez-San Millan et 
al., 2008). Another example is the high-level production of Entamoeba histolytica LacA 
lectin fragment in tobacco chloroplasts (an average yield of 24 mg of LecA per plant) and the 
demonstration of very effective immunogenicity after subcutaneous immunization of mice 
(Chebolu and Daniell, 2007). According to the authors it should translate to 29 million doses 
of vaccine antigen per acre of transgenic plants. Additionally, Scotti et al. (2009) have 
reported that it is possible to produce whole Pr55Gag protein, at levels up to 800 mg⁄kg, in 
transplastomic tobacco. 
Another very encouraging large-scale cost-effective production system is transient 
expression system. Recently Kentucky Bioprocessing Group demonstrated the production of 
approximately 500 g of H1N1 protein using Megnifection technology in tobacco (Hyatt, 
2011). Other examples of successful production using this system are: HBsAg using 
MagnICON viral vectors (approximately 300 mg⁄ kg leaf fresh weight): the product was also 
full-length, had disulphide-linked dimers and assembled into VLPs (Huang et al., 2008); the 
production of lifelong supplies of single- patient personalised non-Hodgkin lymphoma 
vaccines from as little as 5 kg of N. Benthamiana using MagnICON vectors to (Rybicki, 
2009b); human Norwalk norovirus capsid vaccines quickly produced with Icon technology 
(Dylewski, 2009; Rybicki, 2009b) etc.  
 
2. Proof of concept of plant-made oral vaccine 
Challenges: To elicit immune response in most cases at least 10 x doses compared to 
parenteral delivery is required. Since in majority stably integrated nuclear transgenes the level 
of expression is not high enough, it affected to test the proof of concept and efficacy. 
Opportunities: with the above-mentioned success rate of large-scale production using 
the transplastomic and Magninfection transient expression technology it is possible to 
perform the test of proof of concept and efficacy. Oral delivery of several plant-derived 
antigens has elicited antigen-specific antibodies in mice and, in a few clinical trials, in 
humans (Arakawa et al., 1998; Tacket et al., 1998). Examples are: mice orally immunized 
with carrot-derived LTB (Rosales-Mandoza et al., 2008) or rice-derived CTB (Nochi et al., 
2007) induce protection against cholera toxin (CT) challenge. Several other antigens from 
non-enteric pathogens such as F protein from respiratory syncytial virus (Sandhu et al. 2000) 
and surface antigen from hepatitis B (Richter et al., 2000; Thanavala et al., 2005) also 
stimulate antigen-specific antibodies after oral delivery. 
 
3. Very few PMV reached the stage of Phase I Human clinical trial 
Challenges: Although plant-made vaccines have been developed and advanced for two 
decades, none of them have advanced beyond Phase I human clinical trials. 
Opportunities: Notable examples that have had clinical trial success include a 
personalized therapeutic vaccine for non-Hodgkin‘s lymphoma assessed in a Phase I clinical 
trial (McCormick et al., 2008), IFN-a2b to combat hepatitis C assessed in a Phase IIa clinical 
trial (http://www.biolex.com), and human glucocerebrosidase to combat Gaucher‘s disease, 
which has now progressed into a Phase III clinical trial (Aviezeret et al., 2009). 
 
4. Consistency of transgene expression level in different batches and different 
generations 
Challenges: The yield can also vary from plant to plant and generation to generation, 
may be due to gene silencing or position effect (Voinet et al., 2003). 
Opportunities: transient expression technology uses vegetative tissue (leaf) for 
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transgene expression where yield is consistent (very little variation between batches. In case 
of transplastomic technology, gene silencing that causes variation in the Consistency of 
transgene expression level has not yet been reported. Therefore, these technologies offer the 
opportunity to overcome the challenge of transgene expression level consistency. 
 
5. Rapid response to meet sudden pandemic challenges  
Challenges: There are many serious infectious disease pathogens that are highly 
mutable therefore there is a need for Rapid response technologies to meet sudden pandemic 
challenges such as influenza, highly mutable serious pathogens or bioterrorism. 
Opportunities: During the recent new influenza an H1N1 pandemic threat, the most 
impressive demonstration of the potential of plant-produced vaccines by two groups of 
researchers at Medicago Inc. in Canada and at the Fraunhofer USA. They managed to go from 
PubMed-accessed H1 HA sequence, through to purification of grams of protein in less than a 
month, via transient expression in tobacco (Rybicki, 2009b). Moreover, the recent 
demonstration of the ability of KBP to produce 500 g recombinant Hemagglutinin (rHA) in N. 
benthamiana within 30 days of vector construction using MagnICON technology (Hyatt, 
2011). Similarly, VAXX Inc. reported to quickly produce gram quantities of a diarrhoea- 
causing norovirus subunit vaccine (Dylewski, 2009) is also very promising, given that this 
virus too is subject to rapid mutational change. Another review claims that the yield from the 
chloroplast transformation is so high that even it will be possible to combat rapid response 
needs such as bioterrorism (Streatfield, 2006). 
 
6. Expression levels of transgenes in edible parts 
Challenges: Although adequate expression of human immune deficiency virus (HIV) 
p24 antigen was observed in tomato leaves (Zhou et al., 2008), there was a >90% reduction in 
green fruits and no expression was observed in ripe fruits. 
Opportunities: Lettuce (Lactuca sativa L.) chloroplast transformation has also been 
developed and there has been success in expressing the first therapeutic protein (proinsulin) in 
lettuce chloroplasts (Ruhlman et al., 2007). Furthermore, stable nuclear expression systems 
have been developed over three decades and are available in a large number of crops, with the 
ability to facilitate tissue-specific expression and inducible expression in the near future it will 
be possible to obtain desirable expression to be commercially competitive for large-scale 
production. 
 
7. Shelflife of edible parts and Dosage issue 
Challenges: The use of fresh, unprocessed plant materials as vaccines has limitations 
due to its shelf life and uniform dosage issue. Thus, for validated potency and stability some 
form of processing, such as freeze-drying must be applied to produce reproducible product 
batch. 
Opportunities: Both freeze- or air-dried and fresh transgenic tomato fruits showed 
similar immunogenic response for NVCP when fed orally (Zhang et al., 2006). The use of 
seed tissues is more promising due to its extended shelf life and stability for both human and 
animal vaccine candidates. For the development of veterinary products, seed-based vaccines 
are particularly attractive because of convenience in storage and delivery and have 
demonstrated promising results in farmed animal studies (Lamphear et al., 2002).  
 
8. Regulatory approval and public acceptance 
Challenges: Regulatory approval of vaccines for human pathogens will always be 
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more stringent and initial public acceptance of vaccines derived from genetically engineered 
plants will be difficult. 
Opportunities: It is quite possible that the first targets of large-scale production of 
plant-derived vaccines should be diseases of animals, given the easier route to demonstration 
of efficacy, and the potentially far shorter regulatory path for such vaccines - as has been 
demonstrated by Dow with their NDV vaccine (Dow AgroSciences, 2008). 
Recent news on the regulatory front is favourable too: the first European guidelines for 
growing plants producing pharmaceuticals in genetically modified plants – drawn up by the 
European Food Safety Authority (EFSA) – were published on 7th August, 2009 (Gilbert, 
2009). These are apparently consistent with those of the US Food and Drug Administration 
and Department of Agriculture, meaning much of the northern hemisphere now has matching 
guidelines for plant-made pharmaceuticals (PMPs). 
On the regulatory front, the FDA approval of the plant-produced injectable purified 
antibody fragments used as individualized vaccines in human trials for non-Hodgkin 
lymphoma therapy (McCormick et al., 2008) was the first for any injectable human vaccine 
derived from plants, meaning that this route of immunization will open up as well. 
Transgene containment is one of the key features of plastid transformation that 
provides increased biosafety and covers the regulatory issue related to the dispersal of any 
unwanted gene into the environment. In most plant species, plastids show uniparental 
maternal inheritance (Hagemann, 2004), which minimizes the risk of pollen transfer from 
transgenic to conventional varieties or related species. Maternal inheritance and prevention of 
gene flow via pollen has been shown in tobacco and tomato plants (Daniell et al., 1998; Ruf 
et al., 2001). 
 
9. Selection of right antigen for large-scale commercial production 
Challenges: To compete against already established blockbuster generic version of 
important vaccines e.g. HBV which is now cheap enough to be included in the Extended 
Program on Immunization (EPI) universal infant vaccination bundle is always a challenge. 
Opportunities: It is probably not an option to attempt to compete with established 
products, but to use the unique advantage of the plant-made vaccine technology—that is, the 
huge range in scalability and speed of response—to leverage a niche in ‗orphan‘ vaccines or 
emerging disease vaccines or even bioterrorism threats, where other means of production are 
simply too slow to respond (Rybicki, 2010; Hiatt, 2011).  
. 
10. Attraction of big pharmaceutical companies to invest in PMV 
Challenges: To make any vaccine highly cost-effective, guaranteed supply and for 
public acceptance it is important to involve big pharmaceutical companies. However, it is 
always a difficult task to attract big pharmaceutical companies to invest in a new technology 
such as PMV. 
Opportunities: The apparent acceptance by the relevant funding agencies in the USA 
that rapid-response vaccines aimed at potential bioterror agents such as anthrax and 
haemorrhagic fever viruses could easily be made in plants may be a valuable lever in this 
regard. 
 
CONCLUSIONS 
 
In the last 20 years, an impressive amount of research has been conducted in plant-
made vaccine area. As a result diverse plant-based production systems are developed that 
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offers opportunities to produce a wide variety of antigens proteins against diverse diseases 
which can be delivered using different means. There are now registered products, produced 
according to Good Manufacturing Practice (GMP) protocols, entering clinical trials. There are 
presently several independent facilities capable of manufacturing clinical-grade material for 
human trial; products have been in, and there are present and planned, clinical trials (Rybicki, 
2010). However, to move this field forward greater research emphasis is needed on large-
scale production, purification, functional characterization, oral delivery and preclinical 
evaluations (Daniell et al., 2009). 
As per original dream of edible vaccine that is direct consumption of transgenic tissue 
without purification of vaccine protein, uniform dosage and quality control for reproducible 
effect is still a major challenge. It is realized that direct consumption will not be feasible. 
However, quantitation of vaccine protein in freeze- or air-dried edible transgenic tissues and 
minor processing may be used to overcome the issues of uniform dosage and quality control 
for reproducible effect. Food processing technology available in the Food Processing 
Industries will aid in this respect. 
For plant-made vaccines to be successful in the marketplace, it should be of 
comparable in quality and scale and/or better in cost. One transient plant system case study 
demonstrates a fully functional monoclonal antibody conforming to release specifications. 
The production capacity of large quantities of recombinant protein offered by transient plant 
expression systems, coupled with robust downstream purification approaches, offers a 
promising solution to recombinant protein production that compares favourably to cell-based 
systems in scale, cost and quality (Pogue et al., 2010). 
The availability of transient plant virus expression systems utilizing Agrobacterium 
inoculation (Agroinfiltration) methods developed by MagnICON for rapid response to combat 
H1N1 influenza virus, other important highly mutable pathogens or bioterrorism is the best 
scenario where academicians, industries, funding agencies and regulatory agencies could 
work together to move this field forward in a much faster pace.  
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